… (CDDP) is the most active chemotherapeutic agent in Lung Cancer. Here we … lung cancer
(NSCLC) and small cell lung cancer (SCLC) cell lines alone and in combination with Cisplatin (…

… combined with cisplatin and gemcitabine for first-line treatment of advanced NSCLC. Overall,
the erlotinib combination … EGFR TKI gefitinib combined with platinum-based chemotherapy. …

… toxicity of carboplatin with that of cisplatin when both were combined with any third‐generation
drug. We then analysed carboplatin or cisplatin combined with each of the following drugs…

… The optimal dose of paclitaxel given as a 3-hour infusion in the treatment of lung cancer is
less well-defined. Phase I and II trials in which paclitaxel was combined with carboplatin have …

… and small-cell lung tumor xenografts in nude mice. ,18 We previously conducted a phase I
study of the combination of CPT-11 and cisplatin for non-small-cell lung cancer (NSCLC) and …

… We hypothesize that PTEN-deficient lung cancer cells suppressed … (cisplatin) and a PARP
inhibitor (olaparib). To investigate the effect of olaparib and cisplatin on PTEN-deficient lung …

… a standard combination chemotherapy for patients with advanced non-small-cell lung cancer
(… +cisplatin is superior to cisplatin+vindesine and that CPT-11 monotherapy is not inferior to …

… cancers, 1 and it follows a more rapid clinical course than non–small-cell lung cancer. In
contrast to non–small-cell lung cancer, however, small-cell lung cancer is very sensitive to …

… lung cancer (NSCLC). Paclitaxel administered as a single agent or in combination with cisplatin
… cisplatin (100 mg/m 2 ) or a combination of paclitaxel (175 mg/m 2 , 3-hour infusion) and …

… cisplatin‐based chemotherapy, both in combination with a third‐generation drug, in people
with advanced non‐small cell lung cancer (… with cisplatin and carboplatin combined with a …